Zhao Xueyu, Dai Xiaojun, Wang Shanshan, Yang Ting, Yan Yan, Zhu Guang, Feng Jun, Pan Bo, Sunagawa Masataka, Zhang Xiaochun, Qian Yayun, Liu Yanqing
Department of Combined Traditional Chinese and Western Medicine, Yangzhou University School of Medicine, Yangzhou, Jiangsu 225000, China.
Yangzhou Cancer Research Institute, Yangzhou University, Yangzhou, Jiangsu 225009, China.
Evid Based Complement Alternat Med. 2018 Jul 25;2018:4369027. doi: 10.1155/2018/4369027. eCollection 2018.
This study was designed to evaluate the clinical efficacy of combined traditional Chinese medicine (TCM) and conventional chemotherapy versus conventional chemotherapy in patients with stage II-IIIA non-small-cell lung cancer (NSCLC) after radical surgery.
A retrospective cohort study was conducted in patients with stage II-IIIA NSCLC from Subei People's Hospital and Yangzhou Traditional Chinese Medicine Hospital in Yangzhou City of Jiangsu Province from 2012 to 2016. Patients were divided into two groups: the TCM user group (patients receiving treatment with integrated TCM and conventional chemotherapy) and the non-TCM user group (patients receiving conventional chemotherapy only). The two groups were compared for their median disease-free survival (DFS) and median overall survival (OS).
A total of 67 patients with stage II-IIIA NSCLC were enrolled between January 2012 and December 2016. The median DFS for the non-TCM user group was 601 days (95% confidence interval [CI], 375.7-826.3). The median DFS for TCM user group could not be calculated. However, log-rank analysis showed that the median survival time in the TCM user group was significantly longer than that of the non-TCM user group (P < 0.05). In addition, several significant risk factors were detected for predicting disease prognosis in patients with NSCLC, such as age, ECOG, lymphatic metastasis, and body mass index (BMI). For patients harboring these independent risk factors, the DFS of TCM user group was much longer than that of non-TCM user group (P < 0.05).
Adjuvant therapy with TCM may reduce the rate of tumor recurrence and metastasis and prolong DFS of patients with stage II-IIIA NSCLC.
本研究旨在评估中药联合传统化疗与单纯传统化疗在II-IIIA期非小细胞肺癌（NSCLC）根治性手术后患者中的临床疗效。
对2012年至2016年江苏省扬州市苏北人民医院和扬州市中医院的II-IIIA期NSCLC患者进行回顾性队列研究。患者分为两组：中药使用组（接受中药与传统化疗联合治疗的患者）和非中药使用组（仅接受传统化疗的患者）。比较两组的中位无病生存期（DFS）和中位总生存期（OS）。
2012年1月至2016年12月共纳入67例II-IIIA期NSCLC患者。非中药使用组的中位DFS为601天（95%置信区间[CI]，375.7-826.3）。中药使用组的中位DFS无法计算。然而，对数秩分析显示，中药使用组的中位生存时间明显长于非中药使用组（P<0.05）。此外，还检测到一些预测NSCLC患者疾病预后的重要危险因素，如年龄、东部肿瘤协作组（ECOG）评分、淋巴转移和体重指数（BMI）。对于存在这些独立危险因素的患者，中药使用组的DFS远长于非中药使用组（P<0.05）。
中药辅助治疗可能降低II-IIIA期NSCLC患者的肿瘤复发和转移率，并延长DFS。
